Leerink raised the firm’s price target on BridgeBio (BBIO) to $56 from $53 and keeps an Outperform rating on the shares. The firm says that while the shares have largely been driven by Attruby’s launch in ATTR-CM and competitive dynamics vs Alnylam’s (ALNY) Amvuttra, three Phase 3 readouts in the next 9 months begin to diversify the story beyond a single-asset launch story. With infigratinib in achondroplasia the most closely followed pipeline program and encaleret in autosomal dominant hypocalcemia Type 1 the most de-risked, BBP-418 in limb-girdle muscular dystrophy type 2I/R9 presents the most meaningful opportunity to move Street expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $68 from $63 at Piper Sandler
- Cautious Hold Rating for BridgeBio Pharma Amid Attruby Sales Focus and BBP-418 Regulatory Prospects
- BridgeBio Pharma’s Promising Prospects: Buy Rating Driven by BBP-418’s Potential in Rare Neuromuscular Disorder
- BridgeBio Pharma’s Growth Potential Highlighted by Positive Outlook on BBP-418 and FDA Support
- BridgeBio initiated with a Buy at Jefferies